Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 5, No 2 (2012) COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS Abstract  similar documents
A. V. Rudakova
"... paricalcitoldecreases proteinuria in patients with chronic kidney disease (CKD) and hyperparathyreosis. ..."
 
Vol 8, No 4 (2015) CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva
"... ) Eltrombopag and Romiplostim has been performed in patients with chronic idiopathic thrombocytopenic purpura ..."
 
Vol 10, No 3 (2017) The strategies of drug supply for patients with chronic hepatitis C Abstract  similar documents
E. V. Kornilova, A. D. Ermolaeva, M. G. Rusanova, D. A. Andreev, M. V. Davydovskaya, T. N. Ermolaeva, A. g Pokatilo, K. I. Polyakova, V. A. Dubovtseva, K. А. Kokushkin, A. V. Devyatkin
"... The report reviews the options of drug supply for patients with chronic hepatitis C in the Russian ..."
 
Vol 6, No 2 (2013) HTA CORE MODEL Abstract  similar documents
R. I. Yagudina, T. Yu. Nor, A. D. Sevostyanov
"... The EUnetHTA Core Model is an electronic system of standardized health technology assessment ..."
 
Vol 6, No 2 (2013) FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS Abstract  similar documents
A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure
"... Goal: to develop the model of of type 2 diabetes mellitus outcomes validated in Russian clinical ..."
 
Vol 9, No 1 (2016) MATHEMATICAL MODEL OF REIMBURSEMENT DECISION MAKING IN RUSSIA. RESULTS OF VIM LIST FOR 2016 Abstract  similar documents
A. S. Kolbin, A. V. Prasolov, E. A. Maksimkina, Yu. E. Balykina, Z. M. Golant, Yu. S. Polushin, A. A. Kurylev, I. A. Vilyum
"... inclusion and exclusion into the reimbursement lists in Russian Federation. The liner mathematical model ..."
 
Vol 7, No 2 (2014) PARAMETERS OF HEALTH CARE SYSTEMS Abstract  similar documents
V. V. Omelyanovskiy, I. V. Maksimova, A. P. Tatarinov
"... selection of the best model of health care to ensure more efficient use of resources to improve ..."
 
Vol 9, No 2 (2016) PHARMACO-ECONOMIC ANALYSIS OF COST IN TERMS OF MAINTENANCE OF PREFERENTIAL MEDICINES PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ON THE TERRITORY OF KRASNOYARSK REGION Abstract  similar documents
T. V. Gaygolnik, I. V. Demko, E. N. Bochanova, A. Yu. Kraposhina, N. V. Gordeeva, I. A. Soloveva
"... бронходилататорами (73,9%) и комбинацией длительно действующих В2-агонистов (ДДБА) и ингаляционных ..."
 
Vol 7, No 4 (2014) MODELING IN CLINICO-ECONOMIC ANALYSIS OF MEDICAL ORGANIZATIONAL TECHNOLOGIES Abstract  similar documents
M. A. Shapovalova, A. R. Umerova, V. A. Bondarev, L. R. Koretskaya
"... decision tree and Markov model we used for calculating the anticipated costs when comparing two ..."
 
Vol 11, No 2 (2018) Regional adaptation of the federal model of reimbursement for medical assistance based on clinical statistical groups: hospitalization of patients in need of genetically enginered biological preparations Abstract  similar documents
M. V. Sura, T. N. Ignatova, N. S. Rudneva, Yu. N. Sukhanova, N. G. Ulyanova, A. S. Khudyaev, V. A. Shelyakin, D. V. Scherbakov
"... The existing model of financial support of medical assistance for clinical-statistical groups (CSGs ..."
 
Vol 11, No 2 (2018) Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia Abstract  similar documents
N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov
"... Ilmatinib is currently the most widely used tyrosine kinase inhibitor for the treatment of chronic ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC EVALUATION OF RUFINAMIDE USE FOR THE LENNOX-GASTAUT SYNDROME TREATMENT Abstract  similar documents
N. K. Mazina, P. V. Mazin, Yu. V. Kislitsin, E. M. Markova
"... моделирование, модель «дерево решений». Статья поступила: 20.01.2016 г.; в доработанном виде: 26.02.2016 г ..."
 
Vol 11, No 4 (2018) Clinical and economic studies on pharmacotherapy of malignant neoplasms: the modeling approach Abstract  similar documents
A. G. Tolkushin, S. K. Zyryanov, N. L. Pogudina, M. V. Davydovskaya
"... special attention to the model type, the modeling methodology, information on the effectiveness and cost ..."
 
Vol 12, No 1 (2019) Evaluation of the clinical efficacy of anti-asthma pharmacotherapy in children using the software package based on the Fishburn method Abstract  similar documents
O. V. Zhukova, I. V. Nikiforova
"... антагонистов лейкотриеновых рецепторов (АЛР), комбинация ИГКС, длительно действующих β2-агонистов (ДДБА) и АЛР ..."
 
Vol 9, No 3 (2016) COPAYMENTS OF THE CITIZENS IN HEALTHCARE SYSTEM: INTERNATIONAL PRACTICE Abstract  similar documents
A. P. Tatarinov, D. V. Lukyantseva, L. S. Melnikova, V. V. Omelyanovskii
"... , соплатежи, сооплата, сострахование, франшизы, международный опыт, модель здравоохранения, система ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE Abstract  similar documents
A. U. Kulikov, I. A. Komarov
"... Currently, chronic obstructive pulmonary disease (COPD) is a 5-largest cause of death worldwide ..."
 
Vol 6, No 2 (2013) COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... – nilotinib (Tasigna) and imatinib (Gleevec) in CML in the chronic phase (CP) treatment as firstline therapy ..."
 
Vol 6, No 4 (2013) Pharmacoeconomical analysis of use of the low-molecular weight heparins for prevention of the venous tromboembolism in the conditions of multidisciplinary hospital Abstract  similar documents
A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina
"... , two pharmacoeconomic models were constructed. The main model evaluated efficacy of thromboprophylactic ..."
 
Vol 7, No 1 (2014) CLINICAL AND ECONOMIC ANALYSIS IN ASSESSMENT OF HEALTH CARE TECHNOLOGIES IN HEALTH CARE INSTITUTIONS Abstract  similar documents
I. B. Gaykovaya, A. T. Burbello, A. I. Ermakov, A. S. Fedorenko, T. V. Vavilova, M. V. Komok
"... of chronic infectious and inflammatory diseases and to evaluate the effectiveness of antiplatelet therapy. ..."
 
Vol 8, No 2 (2015) REVIEW OF THE INTERNATIONAL PRACTICE OF COST-SHARING MECHANISM IN NATIONAL HEALTH CARE SYSTEMS Abstract  similar documents
Natalia Nikolayevna Sisigina, Vitalii Vladimirovich Omel'yanovskii, Nikolay Alexandrovich Avxentyev
"... mechanisms for vulnerable social groups, national cost-sharing models are considered. ..."
 
Vol 9, No 2 (2016) PHARMACOECONOMIC ANALYSIS OF THE THERAPY OF СHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS IN HOSPITAL CONDITIONS Abstract  similar documents
E. E. Vidyakina, S. V. Malchikova
 
Vol 10, No 3 (2017) Decision modelling for the evaluation of diabetes outcomes Abstract  similar documents
A. A. Mosikian, W. Zhao, T. L. Galankin, A. S. Kolbin
"... DM decision models and on the validity of extrapolating the type 2 DM models to patients with type 1 ..."
 
Vol 8, No 1 (2015) PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION Abstract  similar documents
M. V. Avxentyeva, N. A. Avxentyev, M. Yu. Frolov, E. V. Derkach
"... effectiveness and safety differences of alternatives employing the probability-statistical model. Data on safety ..."
 
Vol 6, No 3 (2013) COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... Chronic myeloid leukemia (CML) accounts for roughly 20% of leucosis in adults, and this pathology ..."
 
Vol 6, No 2 (2013) PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION Abstract  similar documents
V. A. Chibilyaev, A. Yu. Kulikov, R. I. Yagudina
"... B), which differ with the expansion of access to ART was conducted using deterministic model ..."
 
Vol 7, No 2 (2014) CLINICAL AND ECONOMIC EVALUATION OF IVABRADINE USE IN STABLE ANGINA IN TERMS OF REPUBLIC OF BELARUS HEALTH CARE SYSTEM Abstract  similar documents
I. N. Kozhanova, I. S. Romanova, L. N. Gavrilenko, A. V. Patseev, M. M. Sachek
"... system of the Republic of Belarus. Material and methods. Markov’s model of ivabradine use in patients ..."
 
Vol 9, No 3 (2016) HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE Abstract  similar documents
A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, Yu. E. Balykina
"... . At the mean time the model account for the patients compliance and showed that the maximum number of patient ..."
 
Vol 9, No 2 (2016) BUDGET IMPACT ANALYSIS OF PERAMPANEL FOR ADJUNCTIVE TREATMENT IN EPILEPSY PATIENTS 12 YEARS OF AGE AND OLDER FOR PARTIAL ONSET SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION AND PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN THE RUSSIAN FEDERATION Abstract  similar documents
V. R. Mkrtchyan, A. M. Sergeev, K. I. Pochigaeva, I. A. Shpak
"... to five years. The model was developed from a payer perspective with a time horizon of five years. Direct ..."
 
Vol 8, No 1 (2015) PAYMENT OF NEW EXPENSIVE TECHNOLOGIES IN HEALTH CARE ON THE BASIS OF RISKS -SHARING AGREEMENTS: POSSIBILITIES OF APPLICATION IN THE RUSSIAN FEDERATION Abstract  similar documents
L. S. Melnikova
"... The article sets out the results of analysis of existing models of risk sharing agreements, which ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... Excel model. CER compared lenvatinib 24 mg/daily, sorafenib 800 mg/daily and Other chemotherapies mix ..."
 
Vol 5, No 2 (2012) WORKING OUT OF STRATEGY OF STOREKEEPING OF PHARMACEUTICAL FIRM Abstract  similar documents
A. I. Borodin
"... and depending on features of demand optimum strategy of storekeeping with use of dynamic models, periodic ..."
 
Vol 7, No 3 (2014) ECONOMIC JUSTIFICATION FOR TELEHEALTH TECHNOLOGY USE FOR PREVENTIVE MEDICAL EXAMINATION OF THE POPULATION IN REMOTE REGIONS Abstract  similar documents
D. V. Fedyaev, V. K. Fedyaeva, V. V. Omelyanovsky
"... Okrug – Yugra. The model developed medicoeconomic assumes comparison of two possible strategy ..."
 
Vol 9, No 3 (2016) CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov
"... Aims of study: 1) development of a model for forecasting of impact of Lacosamide administration ..."
 
Vol 8, No 1 (2015) SOCIAL AND ECONOMIC BURDEN OF FIVE NATURAL FOCAL INFECTIONS IN THE RUSSIAN FEDERATION Abstract  similar documents
A. E. Platonov, N. A. Avksentyev, M. V. Avksentyeva, E. V. Derkach, O. V. Platonova, A. V. Titkov, N. M. Kolyasnikova
"... ) are calculated in the probability model. Results. The total value of social and economic losses associated ..."
 
Vol 12, No 1 (2019) Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan Abstract  similar documents
T. P. Bezdenezhnykh, D. V. Fedyaev, G. R. Khachatryan, G. G. Arutyunov, K. V. Gerasimova
"... The integrated Model of health care for patients with inflammatory bowel disease (IBD) is based ..."
 
Vol 7, No 3 (2014) MODELI NG CLINICAL AND ECONOMIC OUTCOMES OF TESTING FOR LTBI WITH T-SPOT.TB IN IMMUNOCOMPROMISED CHILDREN Abstract  similar documents
V. I. Ignatyeva, M. V. Avxentyeva, V. V. Omelyanovsky, G. R. Khachatryan
"... .TB in immunocompromised children. Methods: we develope d a model, forecasting the testing results, probable cases ..."
 
Vol 9, No 1 (2016) COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA Abstract  similar documents
G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy
"... was performed in two parts in 2015. In the first part Markov model was built on the basis of the results ..."
 
Vol 10, No 1 (2017) EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... impact and the “cost-effectiveness” parameters were analyzed using the MS Excel-model based on a 3-year ..."
 
Vol 11, No 1 (2018) CYP2D6 genotyping in the daily routine of a psychiatric hospital – pharmacoeconomic evaluation Abstract  similar documents
A. A. Kurylev, B. V. Andreev, A. S. Kolbin, O. V. Limankin
"... decision-making model was created. The model calculates direct medical costs for the patient care ..."
 
Vol 8, No 4 (2015) THE COST OF NUTRITION ALTERNATIVES FOR PREMATURE INFANTS IN RUSSIA Abstract  similar documents
K. V. Gerasimova, M. V. Avxentyeva, I. A. Belyaeva
"... , the BM cost with the use of another model of clinical breast pump and the cost of liquid AF. Sensitivity ..."
 
Vol 10, No 3 (2017) Initiation and intensification of insulin therapy in patients with type 2 diabetes mellitus: a budget impact analysis Abstract  similar documents
E. V. Biryukova, V. I. Ignat’eva
"... created a “decision tree” model that allowed us to calculate the costs of 48-week insulin therapy in 1000 ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis Abstract  similar documents
R. I. Yagudina, M. M. Murashko
"... of the survey data for a particular health facility pharmacoeconomic simulation model was designed. ..."
 
Vol 8, No 2 (2015) ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA Abstract  similar documents
Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov
"... of treatment. Materials and methods. In the Markov's model developed for assessment of long-term clinical ..."
 
Vol 10, No 4 (2017) PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... of medical care. Materials and methods. A mathematical model describing the current (2017) approach ..."
 
Vol 10, No 2 (2017) ECONOMIC ASSESSMENT OF THE EFFECTIVENESS AND SAFETY OF THE COMMONLY PRACTICED PERIOPERATIVE ANTIBIOTIC PROPHYLAXIS (BASED ON AN EARLIER EPIDEMIOLOGICAL SURVEY OF MULTIDISCIPLINARY HOSPITALS) Abstract  similar documents
Yu. M. Gomon, A. S. Kolbin, S. V. Sidorenko, A. M. Kuzhel’, A. V. Repina, Yu. V. Lobzin, Yu. E. Balykina
"... from a multicenter epidemiological survey and previously conducted studies. The Markov model was used ..."
 
Vol 10, No 3 (2017) Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients Abstract  similar documents
N. K. Mazina, P. V. Mazin
"... . The pharmacoeconomic advantages of enzalutamide over the two other agents are supported by the «decision tree» model ..."
 
Vol 11, No 4 (2018) Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease Abstract  similar documents
V. I. Ignatyeva, S. V. Moiseev, N. M. Bulanov, E. A. Karovajkina, A S. Moiseev
"... cases as depending on the time of ERT start. Materials and methods. The proposed model is based ..."
 
Vol 5, No 1 (2012) DYNAMICS OF PREFERENTIAL MAINTENANCE OF CITIZENS WITH ANTIHYPERTENSIVE DRUGS AT THE EXPENSE OF THE REGIONAL BUDGET Abstract  similar documents
I. I. Lavrentyeva, A. I. Khokhlov, I. N. Kagramanyan, T. A. Gorokhova
"... препараты - 6,8 2,5 3,9 Антагонисты рецепторов ангиотензина II - 4,8 2,2 3,5 Агонисты h1 –имидазолиновых ..."
 
1 - 50 of 118 Items 1 2 3 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)